Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

Robert A. Hauser*, Michel Panisset, Giovanni Abbruzzese, Linda Mancione, Nalina Dronamraju, Algirdas Kakarieka, Anwar Ahmed, Alberto Albanese, Ubaldo Bonuccelli, Raif Cakmur, Kelvin Chou, Martin Cloutier, Luis Cunha, Hiren Desai, Ruth Djaldetti, Vaclav Dostal, Bulent Elibol, Murat Emre, Urszula Fiszer, Joseph FriedmanNir Giladi, Stephen Gollomp, Alan Goodridge, David Grimes, Tanya Gurevich, Mark Guttman, Sharon Hassin, Zhigao Huang, Robert Hutchman, Joohi Jimenez-Shahed, Petr Kanovsky, David King, Colin Klein, Scott Kraft, Anne Louise Lafontaine, Leonardo Lopiano, Peter Lewitt, Vojtech Mach, Paul Mazzeo, Giuseppe Meco, Tilak Mendis, Letterio Morgante, Grzegorz Opala, Gianni Pezzoli, Emmanuelle Pourcher, Jose Martin Rabey, Alexander Rajput, Jean Rivest, Mario Miguel Rosa, Michael Rossen, Monika Rudzinska, Stefano Ruggieri, Evzen Ruzicka, Michael Sauter, Dee Silver, Dwight Stewart, William Sunter, Ryan Uitti, Felix Veloso, Mario Zappia, Theresa Zesiewicz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

107 Scopus citations

Fingerprint

Dive into the research topics of 'Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience